Capstan Medical, a provider of heart valve solutions, has secured $110m in a Series C funding round to bring its robotics technology to heart disease patients.
The funding round was led by US-based venture capital firm Eclipse. Existing investors Yu Galaxy and Intuitive Ventures, along with new investor Gideon Strategic Partners, also participated.
This investment will help advance Capstan Medical’s structural heart treatments to reach more patients.
Eclipse partner Justin Butler said: “We’re at an inflection point where robotics will play a consequential role in delivering life-saving solutions to millions of patients across the world.
“Capstan is at the forefront of this wave with their robotic solutions for structural heart disease.”
The Series C round follows the firm’s Series B investment fundraising, in which it collected $31.4m in August 2023.
According to Capstan Medical, current heart valve treatments typically require open-heart surgery, making them unsuitable for many patients. Existing catheter-based options also exclude a significant number of individuals. Said the California-based firm.
The heart valve solutions provider’s minimally invasive solution aims to address these limitations. By combining heart valve implants with advanced catheter technology, all powered by a robotic platform, Capstan Medical expands treatment options for a wider range of patients.
Capstan Medical CEO Maggie Nixon said: “Percutaneous intervention has the opportunity to dramatically increase the treatment options for the millions of people suffering from heart valve disease.
“At Capstan, we believe that our robotic platform with a full portfolio of implants can uniquely address the urgent needs of this underserved patient population.
“We have pulled together the right people at the right time to make this happen and are energised by the incredible support of our investors.”
Founded in 2020, Capstan Medical has assembled a team with expertise in heart valves, implant delivery, and robotics.
The company now employs over 75 people across engineering, operations, clinical, and regulatory roles.
With the new funding, the company will accelerate its clinical and development efforts to support its upcoming trials.
Capstan Medical plans to conduct its first-in-human mitral valve procedure by early next year, followed by a similar procedure for the tricuspid valve in 2025.
